| Literature DB >> 23538987 |
David Burnett1, Patricia Kluding, Charles Porter, Carol Fabian, Jennifer Klemp.
Abstract
Maximal oxygen uptake (VO2max) has been used to assess risk for all-cause mortality and cardiovascular disease (CVD), and low VO2max has recently been associated with increased mortality from breast cancer. The purpose of this study was to determine the proportion of breast cancer survivors with 2 or more risk factors for CVD exhibiting a low VO2max and to determine whether sub-maximal endpoints which could be applied more readily to intervention research would correlate with the maximal treadmill test. We performed a single VO2max test on a treadmill with 30 breast cancer survivors age 30-60 (mean age 50.5 ± 5.6 years) who had 2 or more cardiac risk factors for CVD not related to treatment and who had received systemic therapy and or left chest radiation. Submaximal VO2 endpoints were assessed during the VO2max treadmill test and on an Arc trainer. Resting left ventricular ejection fraction (LVEF) was also assessed by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA). A majority (23/30) of women had a VO2max below the 20th percentile based on their predicted normal values. The group mean resting LVEF was 60.5 ± 5.0%. Submaximal VO2 measures were strongly correlated with the maximal test including; 1) 85% age predicted maximum heart rate VO2 on treadmill, (r = .89; p < 0.001), 2) treadmill VO2 at anaerobic threshold (AT), (r = .83; p < 0.001), and 3) Arc VO2 at AT, (r = .80; p < 0.001). Breast cancer survivors with 2 or more CVD risk factors but normal LVEF had a low cardiorespiratory fitness level compared to normative values in the healthy population placing them at increased risk for breast cancer and cardiovascular mortality. Submaximal VO2 exercise testing endpoints showed a strong correlation with the VO2max test in breast cancer survivors and is a good candidate for testing interventions to improve cardiorespiratory fitness.Entities:
Keywords: Anaerobic threshold; Cardiorespiratory fitness; Cardiovascular disease; Chemotherapy; Exercise testing; Weight loss
Year: 2013 PMID: 23538987 PMCID: PMC3606517 DOI: 10.1186/2193-1801-2-68
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Non-treatment related characteristics
| Variable | Breast cancer survivors ( |
|---|---|
| Age (y) | 50.5 ± 5.6 |
| Time since diagnosis (months) | 58 ± 27 |
| BMI (kg.m-2) | 29.2 ± 5.3 |
| Body fat (%) | 44.5 ± 7.7 |
| Overweight (BMI > 25 kg.m-2) | 25/30 (83%) |
| Hypertension | 8/30 (27%) |
| ↑ LDL | 20/30 (66%) |
| Family history heart disease | 12/30 (40%) |
| Sedentary lifestyle | 10/30 (33%) |
| Smoker | 1/30 (3%) |
Note: BMI, body mass index; LDL, low density lipoprotein.
Treatment related characteristics
| Variable | Breast cancer survivors ( |
|---|---|
| Current Aromatase Inhibitor | 14/30 (47%) |
| Current Tamoxifen | 1/30 (3%) |
| Past Aromatase Inhibitors | 4/30 (13%) |
| Past Tamoxifen | 1/30 (3%) |
| Post-menopausal | 28/30 (93%) |
| Adriamycin/Epirubicin | 24/30 (80%) |
| Herceptin | 8/30 (27%) |
| Left chest radiation | 12/30 (40%) |
Cardiorespiratory outcomes
| Variable | Breast cancer survivors ( |
|---|---|
| Maximal VO2 (mL.kg-1.min-1) | 25.4 ± 5.3 |
| Maximal HR (bpm) | 169 ± 12 |
| VO2 at AT on treadmill (mL.kg-1.min-1) | 20.5 ± 4.3 |
| VO2 at AT on Arc (mL.kg-1.min-1) | 19.0 ± 4.4 |
| VO2 at 85% APMHR (mL.kg-1.min-1) | 19.9 ± 3.0 |
| HR at AT on treadmill (bpm) | 148 ± 13 |
| HR at AT on Arc (bpm) | 144 ± 13 |
| HR at 85% APMHR (bpm) | 144 ± 5 |
| Predicted Maximal HR (bpm) | 170 ± 6 |
| Predicted VO2- 85% APMHR (mL.kg-1.min-1) | 24.5 ± 7.2 |
| Predicted VO2max (mL.kg-1.min-1) | 34.5 ± 8.8 |
| Resting HR (bpm) | 78 ± 10 |
| Maximal O2 pulse (mL/beat) | 11.5 ± 1.5 |
| Pre-Treatment LVEF | 63.2 ± 5.7% |
| Study LVEF | 60.5 ± 5.0% |
Note: HR, heart rate; AT, anaerobic threshold; APMHR, age predicted maximal heart rate; LVEF, left ventricular ejection fractions.
Figure 1The association between (A) treadmill 85% age predicted maximum heart rate endpoint, (B) treadmill AT endpoint, and (C) Arc trainer AT endpoint submaximal tests with maximal oxygen uptake.